GRAL
$47.37
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Recent News
Assessing GRAIL (GRAL) Valuation After Recent Share Price Pullback And Ongoing Growth Challenges
Recent performance snapshot GRAIL (GRAL) has drawn attention after a sharp pullback, with the stock showing a one-month return of 57% and a three-month return of 52%, alongside a one-day move of 3%. For context, the company reports annual revenue of US$147.172m and a net income loss of US$408.351m, with revenue growth of 22% and net income growth of 5% on the latest annual figures provided. See our latest analysis for GRAIL. GRAIL’s share price has retreated sharply in recent weeks, with a 30...
Here’s What Analysts Are Saying About Grail Inc. (GRAL)
Grail Inc. (NASDAQ:GRAL) is one of the best small-cap stocks with huge growth potential. On February 20, Baird cut the price target on Grail Inc. (NASDAQ:GRAL) to $82 from $113 while maintaining an Outperform rating on the shares. The rating update came after the announcement that its NHS study missed its primary endpoint. The same […]
GRAIL (GRAL) Valuation Reassessed After NHS Galleri Trial Setback And Market Selloff
Why GRAIL stock is in focus after the NHS-Galleri setback GRAIL (GRAL) is back in the spotlight after its high profile NHS-Galleri trial failed to reach the primary goal of cutting advanced Stage III IV cancer diagnoses, a result that immediately hit sentiment around the Galleri blood test. See our latest analysis for GRAIL. The share price reaction has been severe, with a 1 day share price return of about a 51% decline and a 7 day share price return of about a 49% decline, taking the stock...
Grail Shares Crashes 50% After Major Cancer Screening Trial Fails Main Goal
Grail's three-year cancer screening trial misses its primary goal, sending shares down sharply
Stock Market Today: Nasdaq Charges Higher As Trump Announces Global Tariff; Nvidia Shares Rise (Live Coverage)
Stock Market Today: Stocks turned higher Friday after the Supreme Court ruled against President's Trump's global tariffs.